

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia.

Kamen A. Tsvetanov,^{*,1,2} Stefano Gazzina,^{*,1,3} Simon P. Jones,¹ John van Swieten,³ Barbara Borroni,⁴ Raquel Sanchez-Valle,⁵ Fermin Moreno,^{6, 7} Robert Laforce Jr,⁸ Caroline Graff,⁹ Matthis Synofzik,^{10,11} Daniela Galimberti,^{12,13} Mario Masellis,¹⁴ Maria Carmela Tartaglia,¹⁵ Elizabeth Finger,¹⁶ Rik Vandenberghe,^{17,18} Alexandre de Mendonça,¹⁹ Fabrizio Tagliavini,²⁰ Isabel Santana,^{21,22,23} Simon Ducharme,^{24,25} Chris Butler,²⁶ Alex Gerhard,²⁷ Adrian Danek,²⁸ Johannes Levin,²⁸ Markus Otto,²⁹ Giovanni Frisoni,^{30,31} Roberta Ghidoni,³² Sandro Sorbi,^{33,34} Jonathan D. Rohrer,³⁵ and James B. Rowe,^{1,2,36} on behalf of the Genetic FTD Initiative, GENFI.[#]

**Joint first authorship*

1 Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

2 Cambridge Centre for Ageing and Neuroscience (Cam-CAN), University of Cambridge and MRC Cognition and Brain Sciences Unit, Cambridge, UK

3 Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands

4 Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

5 Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain

6 Cognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain

7 Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain

8 Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec, Canada

9 Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogenetics, Stockholm, Sweden

10 Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research & Center of Neurology, University of Tübingen, Germany

11 German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

- 29 *12 University of Milan, Centro Dino Ferrari, Milan, Italy*
- 30 *13 Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy*
- 31 *14 LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, Ontario, Canada*
- 32 *15 Toronto Western Hospital, Tanz Centre for Research in Neurodegenerative Disease, Toronto, Ontario, Canada*
- 33 *16 Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada*
- 34 *17 Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium*
- 35 *18 Neurology Service, University Hospitals Leuven, Belgium, Laboratory for Neurobiology, VIB-KU*
- 36 *19 Laboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon,*
37 *Portugal*
- 38 *20 Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy*
- 39 *21 Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal*
- 40 *22 Faculty of Medicine, University of Coimbra, Coimbra, Portugal*
- 41 *23 Centre of Neurosciences and Cell biology, Universidade de Coimbra, Coimbra, Portugal*
- 42 *24 Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Canada*
- 43 *25 McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada*
- 44 *26 Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK*
- 45 *27 Faculty of Medical and Human Sciences, Institute of Brain, Behaviour and Mental Health, The University of Manchester,*
46 *Withington, Manchester, UK*
- 47 *28 Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, German Center for Neurodegenerative*
48 *Diseases (DZNE), Munich, Germany*
- 49 *29 Department of Neurology, University Hospital Ulm, Ulm, Germany*
- 50 *30 Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia,*
51 *Italy*
- 52 *31 Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva,*
53 *Geneva, Switzerland*
- 54 *32 Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy*

55 *33 Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy*

56 *34 Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) "Don Gnocchi", Florence, Italy*

57 *35 Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square,*
58 *London, UK*

59 *36 Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK*

60

61 *# See Appendix for a list of GENFI consortium members.*

62

63 *Correspondence to:*

64 *Kamen A. Tsvetanov*

65 *e-mail: kat35@cam.ac.uk*

66

Keywords (up to five): frontotemporal dementia (FTD), presymptomatic, functional magnetic resonance imaging (fMRI), network connectivity.

67 Abstract

68 INTRODUCTION: The presymptomatic phase of neurodegenerative disease can last many years, with
69 sustained cognitive function despite progressive atrophy. We investigate this phenomenon in familial
70 Frontotemporal dementia (FTD).

71 METHODS: We studied 121 presymptomatic FTD mutation carriers and 134 family members without
72 mutations, using multivariate data-driven approach to link cognitive performance with both structural and
73 functional magnetic resonance imaging. Atrophy and brain network connectivity were compared between
74 groups, in relation to the time from expected symptom onset.

75 RESULTS: There were group differences in brain structure and function, in the absence of differences in
76 cognitive performance. Specifically, we identified behaviourally-relevant structural and functional network
77 differences. Structure-function relationships were similar in both groups, but coupling between functional
78 connectivity and cognition was stronger for carriers than for non-carriers, and increased with proximity to
79 the expected onset of disease.

80 DISCUSSION: Our findings suggest that maintenance of functional network connectivity enables carriers to
81 maintain cognitive performance.

82

83 1. Introduction

84 Across the adult healthy lifespan, the structural and functional properties of brain networks are coupled,
85 and both are predictive of cognitive ability [1,2]. The connections between structure, function and
86 performance have been influential in developing current models of ageing and neurodegeneration [3–5].
87 However, this work contrasts with the emerging evidence of neuropathological and structural changes
88 many years before the onset of symptoms of Alzheimer’s disease and frontotemporal dementia (FTD) [6–
89 8]. Genetic FTD with highly-penetrant gene mutations provides the opportunity to examine the precursors
90 of symptomatic disease. Three main genes account for 10-20% of FTD cases: chromosome 9 open reading
91 frame 72 (*C9orf72*), granulin (*GRN*) and microtubule-associated protein tau (*MAPT*). These genes vary in
92 their phenotypic expression and in the age of onset [9]. Despite pleiotropy [10], environmental and
93 secondary genetic moderation [11,12] all three mutations cause significant structural brain changes in key
94 regions over a decade before the expected age of disease onset [7,13], confirmed by longitudinal studies
95 [14,15].

96 The divergence between early structural change and late cognitive decline begs the question: how do
97 presymptomatic gene carriers stay so well in the face of progressive atrophy? We propose that the answer
98 lies in the maintenance of network dynamics and functional organisation [16]. Across the lifespan,
99 functional brain network connectivity predicts cognitive status [17], and this connectivity-cognition
100 relationship becomes stronger with age [18,19].

101 Our overarching hypothesis is that for those at genetic risk of dementia, the maintenance of network
102 connectivity prevents the manifestation of symptoms despite progressive structural changes. A challenge
103 is that neither the anatomical and functional substrates of cognition nor the targets of neurodegenerative
104 disease are mediated by single brain regions: they are distributed across multi-level and interactive
105 networks. We therefore used a multivariate data-driven approach to identify differences in the
106 multidimensional brain-behaviour relationship between presymptomatic carriers and non-carriers of
107 mutations in FTD genes. We identified key brain networks [20] from a large independent population-based
108 age-matched dataset [21].

109 We tested three key hypotheses: (i) presymptomatic carriers differ from non-carriers in brain structure and
110 brain function, but not in cognitive function, (ii) brain structure and function correlate with performance in

111 both groups, but functional network indices are stronger predictors of cognition in carriers, and (iii) the
112 dependence on network integrity for maintaining cognitive functioning increases as carriers approach the
113 onset of symptoms.

114 2. Methods

115 2.1. Participants

116 Thirteen research sites across Europe and Canada recruited participants as part of an international
117 multicentre partnership, the Genetic Frontotemporal Initiative (GENFI). 313 participants had usable
118 structural and resting state functional magnetic resonance imaging data (MRI) [7,13]. The study was
119 approved by the institutional review boards for each site, and participants providing written informed
120 consent. Five participants were excluded due to excessive head motion (see below), resulting in 308
121 datasets for further analysis.

122 Participants were genotyped based on whether they carried a pathogenic mutation in *MAPT*, *GRN* and
123 *C9orf72*. In this study, we focus on non-carriers (NC, N=134) and presymptomatic carriers (PSC, N=121), i.e.
124 gene carriers with normal cognitive function based on a neurocognitive assessment (see below).
125 Participants and site investigators were blinded to the research genotyping, although a minority of
126 participants had undergone predictive testing outwith the GENFI study. See Table 1 for demographic
127 information of both groups. In keeping with other GENFI reports, the years to expected onset (EYO) were
128 calculated as the difference between age at assessment and mean age at onset within the family [7].

129

130 2.2. Neurocognitive assessment

131 Each participant completed a standard clinical assessment consisting of medical history, family history,
132 functional status and physical examination, in complement with collateral history from a family member or
133 a close friend. In the current study 13 behavioural measures of cognitive function were correlated with
134 neuroimaging measures. These included the Uniform Data Set [22]: the Logical Memory subtest of the
135 Wechsler Memory Scale-Revised with Immediate and Delayed Recall scores, Digit Span forwards and
136 backwards from the Wechsler Memory Scale-Revised, a Digit Symbol Task, Parts A and B of the Trail Making
137 Test, the short version of the Boston Naming Test, and Category Fluency (animals). Additional tests included
138 three subscores of the Letter Fluency and Wechsler Abbreviated Scale of Intelligence Block Design task,
139 and the Mini-Mental State Examination. Latency measures for the Trail Making Test were inverted so that
140 higher values across all tests reflect better performance.

141

142 2.3. Neuroimaging assessment

143 Figure 1 provides a schematic representation of imaging data processing pipeline and the analysis strategy
144 for linking brain-behaviour data. MRI data were acquired using 3T scanners and 1.5T where no 3T scanning
145 was available from various vendors, with optimised scanning protocols to maximise synchronisation across
146 scanners and sites [7,13]. A 3D-structural MRI was acquired on each participant using T1-weighted
147 Magnetic Prepared Rapid Gradient Echo sequence. The co-registered T1 images were segmented to extract
148 probabilistic maps of 6 tissue classes: grey matter (GM), white matter (WM), cerebrospinal fluid (CSF),
149 bone, soft tissue, and residual noise. The native-space GM and WM images were submitted to
150 diffeomorphic registration to create equally represented gene-group template images [DARTEL; 23]. The
151 templates for all tissue types were normalised to the Montreal Neurological Institute template using a 12-
152 parameter affine transformation. The normalised images were smoothed using an 8-mm Gaussian kernel.

153 For resting state fMRI measurements, Echo-Planar Imaging data were acquired with at least six minutes of
154 scanning. The imaging data were analysed using Automatic Analysis [AA 4.0; ,24] pipelines and modules
155 which called relevant functions from SPM12 [25]. To quantify the total motion for each participant, the root
156 mean square volume-to-volume displacement was computed using the approach of Jenkinson et al [26].
157 Participants with 3.5 or more standard deviations above the group mean motion displacement were
158 excluded from further analysis (N = 5). To further ensure that potential group bias in head motion did not
159 affect later analysis of connectivity, we took three further steps: i) fMRI data was further postprocessed
160 using whole-brain Independent Component Analysis (ICA) of single subject time-series denoising, with
161 noise components selected and removed automatically using *a priori* heuristics using the ICA-based
162 algorithm [27], ii) postprocessing of network node time-series (see below) and iii) a subject-specific
163 estimate of head movement for each participant [26] included as a covariate in group-level analysis [28].

164 2.4. Network definition

165 The location of the key cortical regions in each network was identified by spatial-ICA in an independent
166 dataset of 298 age-matched healthy individuals from a large population-based cohort [21]. Full details
167 about preprocessing and node definition are described previously [29]. Four networks commonly affected
168 by neurodegenerative diseases including FTD [20] were identified by spatially matching to pre-existing
169 templates [30]. The node time-series were defined as the first principal component resulting from the

170 singular value decomposition of voxels in an 8-mm radius sphere, which was centred on the peak voxel for
171 each node [18]. Visual representation of the spatial distribution of the nodes is shown in Figure 2.

172 We aimed to further reduce the effects of noise confounds on functional connectivity effects of node time-
173 series using general linear model (GLM) [28]. This model included linear trends, expansions of realignment
174 parameters, as well as average signal in WM and CSF, including their derivative and quadratic regressors
175 from the time-courses of each node. The WM and CSF signals were created by using the average signal
176 across all voxels with corresponding tissue probability larger than 0.7 in associated tissue probability maps
177 available in SPM12. A band-pass filter (0.0078-0.1 Hz) was implemented by including a discrete cosine
178 transform set in the GLM. Finally, the functional connectivity (FC) between each pair of nodes was
179 computed using Pearson's correlation on postprocessed time-series.

180

181 [2.5. Statistical analysis](#)

182 [2.5.1. Group differences in brain structure, function and cognition](#)

183 To assess the group-differences in neuroimaging and behavioural dataset we used multiple linear
184 regression with a well-conditioned shrinkage regularization [31,32] and 10-Fold Cross-Validation [33]. In
185 the analysis of brain structure we used as independent variables the mean grey matter volume (GMV) of
186 246 brain nodes [34]. In the analysis of brain function, we used the functional connectivity between 15
187 nodes, which were part of the four large-scale functional networks described above. In the analysis of
188 cognitive function, the independent variables comprised the performance measures on the 13
189 neuropsychological tests performed outside of the scanner. In all three analyses the dependent variable
190 was the genetic status (PSC vs NC) including age as a covariate of no interest. In addition, in the analysis of
191 neuroimaging data we included scanner site and head motion as additional covariates of no interest.

192 [2.5.2. Brain-behaviour relationships](#)

193 For the brain-behaviour analysis, we adopted a two-level procedure. In the first-level analysis, we assessed
194 the multidimensional brain-behaviour relationships using partial least squares [35]. This analysis described
195 the linear relationships between the two multivariate datasets, namely neuroimaging (either GMV or FC)
196 and behavioural performance, by providing pairs of latent variables (Brain-LVs and Cognition-LVs) as linear
197 combinations of the original variables which are optimised to maximise their covariance. Namely, dataset
198 1 consisted of a brain feature set, which could be either grey matter volume (GMV dataset) or functional

199 connectivity strength between pairs of regions for each individual (FC dataset). Dataset 2 included the
200 performance measures on the 13 tests (i.e. Cognition dataset), as considered in the multiple linear
201 regression analysis of group differences in cognition. Covariates of no interest included head motion,
202 scanner site, gender and handedness.

203 Next, we tested whether the identified behaviourally-relevant LVs of brain structure and function were
204 differentially expressed by NC and PSC as a function of expected years to onset. To this end, we performed
205 a second-level analysis using multiple linear regression with robust fitting algorithm as implemented in
206 matlab's function "fitlm.m". Independent variables included subjects' brain scores from first level PLS
207 (either Structure-LV or Function-LV subject scores), group information, expected years to onset and their
208 interaction terms (e.g. brain scores x group, brain scores x years to expected onset, etc.). The dependent
209 variable was subjects' cognitive scores from the first level analysis in the corresponding PLS (Cognition-LV).
210 Covariates of no interest included gender, handedness, head movement and education (Figure 1).

211 3. Results

212 3.1. Group differences in neuroimaging and cognitive data

213 *Brain structure*

214 The multiple linear regression model testing for overall group differences in grey matter volume between
215 PSC and NC was significant ($r=.14$, $p=.025$), reflecting expected presymptomatic differences in brain-wide
216 atrophy. The frontal, parietal and subcortical regions had most atrophy in PSC (Figure 3). As expected, the
217 group difference in grey matter volume of these regions increased as EYO decreased, see Supplementary
218 Materials.

219 *Brain Function*

220 The multiple linear regression model testing for overall group differences in functional connectivity
221 between PSC and NC was marginally significant ($r=.12$, $p=.049$). The pattern of connectivity indicated mainly
222 increased connectivity between SN-DMN and SN-FPN in presymptomatic carriers, coupled with decreased
223 connectivity within the networks and DMN-FPN connectivity (Figure 3).

224 *Cognitive Function*

225 We did not identify group differences in cognition and behaviour ($r=.002$, $p=.807$), confirming the
226 impression of "healthy" status among presymptomatic carriers. However, in the next section, we consider

227 the relationships between structure, function and cognition that underlie this maintenance of cognitive
228 function.

229 3.2. Brain-behaviour relationships

230 *Structure-cognition*

231 Partial least squares analysis of grey matter volume and cognition identified one significant pair of latent
232 variables ($r = .40$, $p = .009$). This volumetric latent variable expressed negative loadings in frontal (superior
233 frontal gyrus, precentral gyrus, paracentral lobule), parietal (postcentral gyrus, precuneus, superior and
234 inferior parietal lobule) and occipital (lateral and medial occipital cortex) regions and positive loadings in
235 parahippocampal and hippocampal regions (Figure 4). The Cognition-LV profile expressed positively a large
236 array of cognitive tests, with strongest values on delayed memory, Trail Making, Digit Symbol, Boston
237 Naming and Fluency tests. The positive correlation between volumetric and cognitive LV's confirms the
238 expected relationship across the cohort as a whole, between cortical grey matter volume and both
239 executive, language and mnemonic function (Figure 4).

240 To understand the structure-cognition relationship in each group and in relation to the expected
241 years of onset, we performed a second-level moderation analysis using a regression model: we entered
242 Cognition-LV subject scores as dependent variable, and grey matter volume LV subject scores, genetic
243 status (i.e. carrier or non-carrier), expected years to onset and their interactions as independent variables
244 in addition to covariates of no interest. The results indicated that the relationship between grey matter
245 volume and cognition could not be explained by genetic status, expected years to onset or their interactions
246 with grey matter volume LV subject scores. There was no evidence for genetic status- and onset-dependent
247 differences (over and above ageing and other covariates) in the associations between grey matter volume
248 and cognition in this analysis (Figure 4).

249 *Connectivity-Cognition*

250 PLS analysis of functional connectivity and cognition also identified one significant pair of LVs (Function-LV
251 and Cognition-LV, $r=.32$, $p=.020$), see Figure 5. This Function-LV reflected weak between-network
252 connectivity, coupled with strong within-network connectivity. This pattern indicates the segregation or
253 modularity of large-scale brain networks. The Cognition-LV expressed all tests, with positive loading values
254 indicating that higher performance on a wide range of cognitive tests is associated with stronger functional
255 network segregation. Cognitive deficits were associated with loss of segregation, with increased between-
256 network connectivity and decreased within-network connectivity.

257 To further test whether the observed behaviourally-relevant pattern of connectivity is differentially
258 expressed between genetic status groups and expected years of onset, we constructed a second-level
259 regression model with robust error estimates by including Function-LV subject scores, genetic status,
260 expected years of onset and their interaction terms as independent variables and Cognition-LV as
261 dependent variable in addition to covariates of no interest (Figure 5).

262 We found evidence for significant interaction between expected years of onset and Function-LV ($r=.21$,
263 $p<.001$) and between group and Function-LV ($r=.15$, $p=.003$) explaining unique variance in Cognition-LV.
264 We used the Dawson and Richter approach [36] to test formally for differences in the relationship (i.e.
265 simple slopes) between Function-LV and Cognition-LV for PSC and NC. The relationship between Function-
266 LV and Cognition-LV was stronger for PSC relative to NC ($r=.15$, $p=.003$), indicating the increasing
267 importance of functional connectivity between the large-scale networks for PSC participants to maintain
268 performance (Figure 5).

269 For ease of interpretation and illustration, we also computed the correlation between Cognition-LV and
270 Function-LV for high and low levels of expected years to onset (EYO) within each group separately, where
271 the levels were taken to be 1 standard deviation above and below the mean values of EYO. The two EYO
272 subgroups were labelled “near” and “far”, with “near” for EYO values close to zero (i.e. participant’s age is
273 “near” the age at which disease symptoms were demonstrated in the family), and “far” for EYO being a
274 largely negative value (i.e. participant’s age is “far” from the age at which disease symptoms were
275 demonstrated in the family). The analysis indicated that as the EYO decreases (i.e. participant’s age is
276 reaching the years of onset of symptoms) the relationship between functional connectivity and
277 performance becomes stronger (moderation effects: $r=.14$, $p=.021$ and $r=.28$, $p<.001$ for NC and PSC,
278 respectively). Interestingly this relationship was stronger in each EYO subgroup for PSC relative to NC (PSC-
279 Near vs NC-Near: $r=.28$, $p<.001$; PSC-Far vs NC-Far: $r=.22$, $p=.001$). These findings indicate that the
280 relationship between FC and cognition is stronger in PSC relative to NC, and that this relationship increases
281 as a function of EYO.

282

283 4. Discussion

284 In the present study, we confirmed previous findings of group differences in brain structure and function,
285 in the absence of differences in cognitive performance between non-carriers and presymptomatic carriers

286 of FTD-related genetic mutations. But, while the relationship between structure and cognition was similar
287 in both groups, the coupling between function and cognition was stronger for presymptomatic carriers,
288 and increased as they approached the expected onset of disease.

289 These results suggest that people can maintain good cognitive abilities and successful day-to-day
290 functioning despite significant neuronal loss and atrophy. This disjunction between structure and function
291 is a feature of healthy ageing, but we have shown that it also characterises presymptomatic FTD, over and
292 above the age effects in their other family members, despite widespread progressive atrophy. The
293 multivariate approach reveals two key findings: (i) presymptomatic carriers express stronger between-
294 network and weaker within-network functional connectivity than age-matched non-carriers, and (ii) as
295 carriers approach their estimated age of symptom onset, and atrophy becomes evident, the maintenance
296 of good cognition is increasingly associated with sustaining balance of within- and between-network
297 integration.

298 This balance of within- and between-network connectivity is characteristic of segregated and specialized
299 network organization of brain systems. Such functional segregation varies with physiological ageing
300 [17,18,37], with cognitive function [18] and in individuals at risk for Alzheimer's disease [38]. Graph-
301 theoretic quantification of network organisation confirms the relevance of modularity and efficiency to
302 function in FTD [16]. Conversely, the loss of neural systems' modularity mirrors the loss of functional
303 specialization with age [39] and dementia [38]. Here, we show the significance of the maintenance of this
304 functional network organisation, with a progressively stronger correlation with cognitive performance as
305 seemingly healthy adults approach the age of expected onset of FTD.

306 The uncoupling of brain function from brain structure indicates that there may be independent and
307 synergistic effects of multiple factors leading to cognitive preservation. This is consistent with a previous
308 work in healthy ageing where brain activity and connectivity provide independent and synergistic
309 predictions of performance across the lifespan [19]. Therefore, future studies need to consider the
310 independent and synergistic effects of many possible biomarkers, based on MRI, computed tomography,
311 positron-emission tomography, CSF, blood and brain histopathology. For example, functional network
312 impairment may be related to tau expression and tau pathology, amyloid load, or neurotransmitter deficits
313 in neurodegenerative diseases, independent of atrophy [29,40–42]. Importantly, studies need to recognise
314 the rich multivariate nature of cognition and of neuroimaging in order to improve stratification procedures,
315 e.g. based on integrative approaches that explain individual differences in cognitive impairment [29,43].

316 We also recognise the difficulty to determine a unique contribution of each factor (e.g. brain structure and
317 brain function), given the increasing interaction between factors in advanced stages of disease [44]. This is
318 further complicated by these alterations becoming irreversible with progression of neurodegeneration
319 [45]. This suggests that the critical interplay between multiple factors (including brain structure and
320 function) may be better studied in the asymptomatic and preclinical stages as well as across the healthy
321 lifespan, which could still be modifiable and their influences are likely to be more separable.

322 Our findings agree with the model of compensation in the presymptomatic and early phases of
323 Huntington's disease, where network coupling predicted better cognitive performance [46]. In a recent
324 longitudinal study a non-linear concave-down pattern of both brain activity and behaviour was present,
325 despite a linear decline in brain volume over time, [47]. Similar effects have been observed also in healthy
326 ageing and amnesic mild cognitive impairment, where greater connectivity with the default-mode network
327 and weaker connectivity between default-mode network and dorsal-attention network was associated with
328 higher cognitive status in both groups [48]. Network integrity may also play a role in compensatory
329 mechanisms in non-cognitive symptoms, such as motor impairment in Parkinson's disease [49].
330 Accordingly, increased network efficiency and connectivity has been shown in prodromal phases, followed
331 by decreased local connectivity in symptomatic phases, suggesting the emergence and dissipation of neural
332 compensation [50].

333 The current study has several limitations. First, despite the large sample of subjects included, we did not
334 analyse each gene separately, as it may have resulted in too small and unbalanced samples, lowering
335 statistical power and robustness. Moreover, genetic FTD is also characterised by multiple mutations within
336 these genes and pleiotropy of clinical phenotypes even for the same mutation [10]. Pleiotropy in terms of
337 clinical phenotype is avoided by the study of presymptomatic carriers, but we cannot rule out pleiotropy
338 of intermediate phenotypes expressed as say neural network diversity. Furthermore, clinical heterogeneity
339 is modified by environmental factors such as education [which may be a surrogate of cognitive reserve, 51],
340 in FTD as in other dementias [12]. Genetic modifiers such as TMEM106B [52], APOE [53], have also been
341 identified. Further work, with larger cohorts, will be able to test the potential effect of these moderators
342 on the relationships between brain structure, functional networks and cognition. Future studies will benefit
343 from using brain measures that reflect differences in neural connectivity directly from neurophysiology or
344 separation of neurovascular from neuronal contributors to BOLD fMRI variance [18,54], which can
345 confound the effects of age, drug or disease [55].

346 The current study is cross-sectional. Therefore, we cannot infer longitudinal progression within subjects as
347 the unambiguous cause of the effects we observe in relation to expected years of onset. Accumulating
348 evidence suggests that network integrity serves to maintain performance with either physiological ageing
349 or pathological conditions. However, longitudinal mediation studies and pharmacological or electroceutical
350 interventions would be needed to prove its causal role in cognitive preservation. Finally, our findings are
351 limited to autosomal dominant FTD, which represents a minority of FTD: generalisation to sporadic forms
352 of disease would be speculative.

353 In conclusion, we used a multivariate data-driven approach to demonstrate that brain functional integrity
354 can enable presymptomatic carriers to maintain cognitive performance in the presence of progressive brain
355 atrophy for years before the onset of symptoms. The approach and the findings have implications for the
356 design of presymptomatic disease-modifying therapy trials and the study of unique and synergistic effects
357 of risk factors and biomarkers in health and disease, which are otherwise increasingly interacting and
358 irreversible with progression of neurodegeneration.

359

360

361 5. References

362

363 [1] Persson J, Nyberg L, Lind J, Larsson A, Nilsson LG, Ingvar M, et al. Structure-function correlates of
364 cognitive decline in aging. *CerebCortex* 2006;16:907–15.

365 [2] Geerligs L, Cam-CAN, Henson RN. Functional connectivity and structural covariance between
366 regions of interest can be measured more accurately using multivariate distance correlation.
367 *Neuroimage* 2016;135:16–31. doi:10.1016/j.neuroimage.2016.04.047.

368 [3] Cope TE, Rittman T, Borchert RJ, Jones PS, Vatansever D, Allinson K, et al. Tau burden and the
369 functional connectome in Alzheimer’s disease and progressive supranuclear palsy. *Brain*
370 2018;141:550–67. doi:10.1093/brain/awx347.

371 [4] Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-
372 scale human brain networks. *Neuron* 2009;62:42–52. doi:10.1016/j.neuron.2009.03.024.

373 [5] Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia.
374 *Neuron* 2012;73:1204–15. doi:10.1016/j.neuron.2011.12.040.

375 [6] Kinnunen KM, Cash DM, Poole T, Frost C, Benzinger TLS, Ahsan RL, et al. Presymptomatic atrophy
376 in autosomal dominant Alzheimer’s disease: A serial magnetic resonance imaging study.
377 *Alzheimer’s Dement* 2018;14:43–53. doi:10.1016/j.jalz.2017.06.2268.

378 [7] Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L, et al. Presymptomatic
379 cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic
380 Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. *Lancet Neurol*
381 2015;14:253–62. doi:10.1016/S1474-4422(14)70324-2.

382 [8] Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JNS, Trujillo A, et al. Timing and
383 significance of pathological features in *C9orf72* expansion-associated frontotemporal dementia.
384 *Brain* 2016;139:3202–16. doi:10.1093/brain/aww250.

385 [9] Deleon J, Miller BL. Frontotemporal dementia, 2018, p. 409–30. doi:10.1016/B978-0-444-64076-
386 5.00027-2.

- 387 [10] Snowden JS, Adams J, Harris J, Thompson JC, Rollinson S, Richardson A, et al. Distinct clinical and
388 pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72
389 mutations. *Amyotroph Lateral Scler Front Degener* 2015;16:497–505.
390 doi:10.3109/21678421.2015.1074700.
- 391 [11] Murphy NA, Arthur KC, Tienari PJ, Houlden H, Chiò A, Traynor BJ. Age-related penetrance of the
392 C9orf72 repeat expansion. *Sci Rep* 2017;7:2116. doi:10.1038/s41598-017-02364-1.
- 393 [12] Premi E, Grassi M, Van Swieten J, Galimberti D, Graff C, Masellis M, et al. Cognitive reserve and
394 TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a
395 GENFI study. *Brain* 2017;140:1784–91. doi:10.1093/brain/awx103.
- 396 [13] Cash DM, Bocchetta M, Thomas DL, Dick KM, van Swieten JC, Borroni B, et al. Patterns of gray
397 matter atrophy in genetic frontotemporal dementia: results from the GENFI study. *Neurobiol Aging*
398 2018;62:191–6. doi:10.1016/j.neurobiolaging.2017.10.008.
- 399 [14] Olm CA, McMillan CT, Irwin DJ, Van Deerlin VM, Cook PA, Gee JC, et al. Longitudinal structural gray
400 matter and white matter MRI changes in presymptomatic progranulin mutation carriers.
401 *NeuroImage Clin* 2018;19:497–506. doi:10.1016/J.NICL.2018.05.017.
- 402 [15] Floeter MK, Danielian LE, Braun LE, Wu T. Longitudinal diffusion imaging across the *C9orf72* clinical
403 spectrum. *J Neurol Neurosurg Psychiatry* 2018;89:53–60. doi:10.1136/jnnp-2017-316799.
- 404 [16] Rittman DT, Borchert MR, Jones MS, van Swieten J, Borroni B, Galimberti D, et al. Functional
405 network resilience to pathology in presymptomatic genetic frontotemporal dementia. *Neurobiol*
406 *Aging* 2019;77:169–77. doi:10.1016/J.NEUROBIOLAGING.2018.12.009.
- 407 [17] Chan MY, Park DC, Savalia NK, Petersen SE, Wig GS. Decreased segregation of brain systems across
408 the healthy adult lifespan. *Proc Natl Acad Sci* 2014;111:4997–5006.
409 doi:10.1073/pnas.1415122111.
- 410 [18] Tsvetanov KA, Henson RNA, Tyler LK, Razi A, Geerligs L, Ham TE, et al. Extrinsic and intrinsic brain
411 network connectivity maintains cognition across the lifespan despite accelerated decay of regional
412 brain activation. *J Neurosci* 2016;36:3115–26. doi:10.1523/JNEUROSCI.2733-15.2016.
- 413 [19] Tsvetanov KA, Ye Z, Hughes L, Samu D, Treder MS, Wolpe N, et al. Activity and connectivity
414 differences underlying inhibitory control across the adult lifespan. *J Neurosci* 2018;38:7887–900.

- 415 doi:10.1523/JNEUROSCI.2919-17.2018.
- 416 [20] Chhatwal JP, Schultz AP, Johnson KA, Hedden T, Jaimes S, Benzinger TLS, et al. Preferential
417 degradation of cognitive networks differentiates Alzheimer’s disease from ageing. *Brain*
418 2018;141:1486–500. doi:10.1093/brain/awy053.
- 419 [21] Shafto MA, Tyler LK, Dixon M, Taylor JR, Rowe JB, Cusack R, et al. The Cambridge Centre for Ageing
420 and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary
421 examination of healthy cognitive ageing. *BMC Neurol* 2014;14:204. doi:10.1186/s12883-014-0204-
422 1.
- 423 [22] Morris JC, Weintraub S, Chui HC, Cummings J, DeCarli C, Ferris S, et al. The Uniform Data Set (UDS):
424 Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers. *Alzheimer*
425 *Dis Assoc Disord* 2006;20:210–6. doi:10.1097/01.wad.0000213865.09806.92.
- 426 [23] Ashburner J. A fast diffeomorphic image registration algorithm. *Neuroimage* 2007;38:95–113.
427 doi:10.1016/j.neuroimage.2007.07.007.
- 428 [24] Cusack R, Vicente-Grabovetsky A, Mitchell DJ, Wild CJ, Auer T, Linke AC, et al. Automatic analysis
429 (aa): efficient neuroimaging workflows and parallel processing using Matlab and XML. *Front*
430 *Neuroinform* 2014;8:90. doi:10.3389/fninf.2014.00090.
- 431 [25] Friston KJ, Ashburner J, Kiebel S, Nichols T, Penny WD. *Statistical parametric mapping : the analysis*
432 *of functional brain images*. Elsevier Academic Press; 2007.
- 433 [26] Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate
434 linear registration and motion correction of brain images. *Neuroimage* 2002;17:825–41.
- 435 [27] Pruim RHR, Mennes M, Buitelaar JK, Beckmann CF. Evaluation of ICA-AROMA and alternative
436 strategies for motion artifact removal in resting state fMRI. *Neuroimage* 2015;112:278–87.
437 doi:10.1016/j.neuroimage.2015.02.063.
- 438 [28] Geerligs L, Tsvetanov KA, Cam-Can, Henson RN. Challenges in measuring individual differences in
439 functional connectivity using fMRI: The case of healthy aging. *Hum Brain Mapp* 2017.
440 doi:10.1002/hbm.23653.
- 441 [29] Passamonti L, Tsvetanov KA, Jones PS, Bevan-Jones WR, Arnold R, Borchert RJ, et al.

- 442 Neuroinflammation and functional connectivity in Alzheimer's disease: interactive influences on
443 cognitive performance. *BioRxiv Prepr* 2019. doi:10.1101/532291.
- 444 [30] Shirer WR, Ryali S, Rykhlevskaia E, Menon V, Greicius MD. Decoding subject-driven cognitive states
445 with whole-brain connectivity patterns. *Cereb Cortex* 2012;22:158–65.
446 doi:10.1093/cercor/bhr099.
- 447 [31] Blankertz B, Lemm S, Treder M, Haufe S, Müller K-R. Single-trial analysis and classification of ERP
448 components--a tutorial. *Neuroimage* 2011;56:814–25. doi:10.1016/j.neuroimage.2010.06.048.
- 449 [32] Ledoit O, Wolf M. A well-conditioned estimator for large-dimensional covariance matrices. *J*
450 *Multivar Anal* 2004;88:365–411. doi:10.1016/S0047-259X(03)00096-4.
- 451 [33] Lemm S, Blankertz B, Dickhaus T, Müller K-R. Introduction to machine learning for brain imaging.
452 *Neuroimage* 2011;56:387–99. doi:10.1016/j.neuroimage.2010.11.004.
- 453 [34] Fan L, Li H, Zhuo J, Zhang Y, Wang J, Chen L, et al. The Human Brainnetome Atlas: A New Brain Atlas
454 Based on Connectional Architecture. *Cereb Cortex* 2016;26:3508–26. doi:10.1093/cercor/bhw157.
- 455 [35] Krishnan A, Williams LJ, McIntosh AR, Abdi H. Partial Least Squares (PLS) methods for
456 neuroimaging: A tutorial and review. *Neuroimage* 2011;56:455–75.
457 doi:10.1016/j.neuroimage.2010.07.034.
- 458 [36] Dawson JF, Richter AW. Probing three-way interactions in moderated multiple regression:
459 Development and application of a slope difference test. *J Appl Psychol* 2006;91:917–26.
460 doi:10.1037/0021-9010.91.4.917.
- 461 [37] Samu D, Campbell KL, Tsvetanov KA, Shafto MA, Consortium C-C, Brayne C, et al. Preserved
462 cognitive functions with age are determined by domain-dependent shifts in network responsivity.
463 *Nat Commun* 2017;8:ncomms14743. doi:10.1038/ncomms14743.
- 464 [38] Contreras JA, Goñi J, Risacher SL, Amico E, Yoder K, Dziedzic M, et al. Cognitive complaints in
465 older adults at risk for Alzheimer's disease are associated with altered resting-state networks.
466 *Alzheimer's Dement Diagnosis, Assess Dis Monit* 2017;6:40–9. doi:10.1016/J.DADM.2016.12.004.
- 467 [39] Cabeza R, Albert M, Belleville S, Craik FIM, Duarte A, Grady CL, et al. Maintenance, reserve and
468 compensation: the cognitive neuroscience of healthy ageing. *Nat Rev Neurosci* 2018;19:701–10.

- 469 doi:10.1038/s41583-018-0068-2.
- 470 [40] Hedden T, Van Dijk KRA, Becker JA, Mehta A, Sperling RA, Johnson KA, et al. Disruption of functional
471 connectivity in clinically normal older adults harboring amyloid burden. *J Neurosci* 2009;29:12686–
472 94. doi:10.1523/JNEUROSCI.3189-09.2009.
- 473 [41] Murley AG, Rowe JB. Neurotransmitter deficits from frontotemporal lobar degeneration. *Brain*
474 2018;141:1263–85. doi:10.1093/brain/awx327.
- 475 [42] Rittman T, Rubinov M, Vértes PE, Patel AX, Ginestet CE, Ghosh BCP, et al. Regional expression of
476 the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in
477 Parkinson disease and progressive supranuclear palsy. *Neurobiol Aging* 2016;48:153–60.
478 doi:10.1016/J.NEUROBIOLAGING.2016.09.001.
- 479 [43] Geerligs L, Tsvetanov KAKA. The use of resting state data in an integrative approach to studying
480 neurocognitive ageing – Commentary on Campbell and Schacter (2016). *Lang Cogn Neurosci*
481 2016;32. doi:http://dx.doi.org/10.1080/23273798.2016.1251600.
- 482 [44] Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Preboske GM, Kantarci K, et al. Vascular and
483 amyloid pathologies are independent predictors of cognitive decline in normal elderly. *Brain*
484 2015;138:761–71. doi:10.1093/brain/awu393.
- 485 [45] Rodrigue KM, Kennedy KM, Devous MD, Rieck JR, Hebrank AC, Diaz-Arrastia R, et al. β -Amyloid
486 burden in healthy aging: regional distribution and cognitive consequences. *Neurology*
487 2012;78:387–95. doi:10.1212/WNL.0b013e318245d295.
- 488 [46] Klöppel S, Gregory S, Scheller E, Minkova L, Razi A, Durr A, et al. Compensation in Preclinical
489 Huntington’s Disease: Evidence From the Track-On HD Study. *EBioMedicine* 2015;2:1420–9.
490 doi:10.1016/j.ebiom.2015.08.002.
- 491 [47] Gregory S, Long JD, Klöppel S, Razi A, Scheller E, Minkova L, et al. Operationalizing compensation
492 over time in neurodegenerative disease. *Brain* 2017;140:1158–65. doi:10.1093/brain/awx022.
- 493 [48] Sullivan MD, Anderson JAE, Turner GR, Spreng RN. Intrinsic neurocognitive network connectivity
494 differences between normal aging and mild cognitive impairment are associated with cognitive
495 status and age. *Neurobiol Aging* 2019;73:219–28. doi:10.1016/J.NEUROBIOLAGING.2018.10.001.

- 496 [49] Blesa J, Trigo-Damas I, Dileone M, del Rey NL-G, Hernandez LF, Obeso JA. Compensatory
497 mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification. *Exp*
498 *Neurol* 2017;298:148–61. doi:10.1016/J.EXPNEUROL.2017.10.002.
- 499 [50] Wen M-C, Heng HSE, Hsu J-L, Xu Z, Liew GM, Au WL, et al. Structural connectome alterations in
500 prodromal and de novo Parkinson's disease patients. *Parkinsonism Relat Disord* 2017;45:21–7.
501 doi:10.1016/j.parkreldis.2017.09.019.
- 502 [51] Stern Y. Cognitive reserve in ageing and Alzheimer's disease. *Lancet Neurol* 2012;11:1006–12.
503 doi:10.1016/S1474-4422(12)70191-6.
- 504 [52] Lattante S, Le Ber I, Galimberti D, Serpente M, Rivaud-Péchoux S, Camuzat A, et al. Defining the
505 association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN
506 mutations and C9orf72 repeat expansions. *Neurobiol Aging* 2014;35:2658.e1-2658.e5.
507 doi:10.1016/J.NEUROBIOLAGING.2014.06.023.
- 508 [53] Koriath C, Kenny J, Adamson G, Drueyeh R, Taylor W, Beck J, et al. Predictors for a dementia gene
509 mutation based on gene-panel next-generation sequencing of a large dementia referral series. *Mol*
510 *Psychiatry* 2018. doi:10.1038/s41380-018-0224-0.
- 511 [54] Sami S, Williams N, Hughes LE, Cope TE, Rittman T, Coyle-Gilchrist ITS, et al. Neurophysiological
512 signatures of Alzheimer's disease and frontotemporal lobar degeneration: pathology versus
513 phenotype. *Brain* 2018;141:2500–10. doi:10.1093/brain/awy180.
- 514 [55] Campbell KL, Shafto MA, Wright P, Tsvetanov KA, Geerligs L, Cusack R, et al. Idiosyncratic
515 responding during movie-watching predicted by age differences in attentional control. *Neurobiol*
516 *Aging* 2015;36:3045–55. doi:10.1016/j.neurobiolaging.2015.07.028.
- 517
- 518
- 519

520

521 6. Acknowledgements

522 Kamen A. Tsvetanov is supported by the British Academy (Postdoctoral Fellowship, PF160048).

523 James B Rowe is supported by the Wellcome Trust (103838) the Medical Research Council (SUAG/051

524 G101400) and the Cambridge NIHR Biomedical Research Centre. Raquel Sánchez-Valle is supported by the

525 Instituto de Salud Carlos III and the JPND network PreFrontAIs (01ED1512/AC14/0013) and the Fundació

526 Marató de TV3 (20143810).

527

528

529 7. Tables


530 *Table 1. Demographics of participants included in the analysis, grouped by genetic status*
 531 *as non-carriers (NC) and presymptomatic carriers (PSC). * denotes whether demographics vary*
 532 *between NC and PSC groups.*

	Gene Carrier Group		Statistical tests*	
	NC	PSC	X ² or F-test	P-value
N	134	121		
Age			2.68	0.103
Mean / SD	49 / 14	46 / 11		
Range [Min/Max]	19 / 86	20 / 70		
Gender, n (%)			0.01	0.908
Men	53 (39.6)	47 (38.8)		
Women	81 (60.4)	74 (61.2)		
Expected Years to Onset			0.23	0.631
Mean / SD	-10 / 12	-11 / 11		
Range [Min/Max]	-25 / 10	-25 / 10		
Education			0.05	0.826
Mean / SD	14 / 3	14 / 3		
Range [Min/Max]	5 / 24	5 / 22		
Mini-Mental State Examination			0.39	0.532
Mean / SD	29 / 1	29 / 1		
Range [Min/Max]	25 / 30	23 / 30		

533


534 8. Figures

535



536

537 *Figure 1. Schematic representation of data processing and analysis pipeline to test for*
 538 *brain-behaviour differences between presymptomatic carriers (PSC) and non-carriers (NC) as a*
 539 *function of expected years to onset (EYO) of symptoms, while controlling for covariates of no*
 540 *interest (Covs). Brain structural measures were based on the mean grey matter volume (GMV) in*
 541 *246 nodes, as defined in the Brainnetome atlas [34]. Brain functional measures were based on the*
 542 *functional connectivity between 15 nodes as part of four large-scale networks, which were defined*
 543 *in an independent cohort of 298 age-matched individuals part of the Cam-CAN dataset*
 544 *(Passamonti et al 2019 BioArxiv).*




545

546 *Figure 2. Visualisation of spatial localisation of the nodes part of the four large-scale*
 547 *networks and their mean functional connectivity (circular plot) across all participants in this study.*
 548 *Nodes and networks were defined in an independent cohort of 298 age-matched individuals part*
 549 *of the Cam-CAN dataset (Passamonti et al 2019). The default mode network (DMN) contained five*
 550 *nodes: the ventral anterior cingulate cortex (vACC), dorsal and ventral posterior cingulate cortex*
 551 *(vPCC and dPCC), and right and left inferior parietal lobes (rIPL and lIPL). The salience network*
 552 *(SN) was defined using right and left anterior insular (rAI and lAI) and dorsal anterior cingulate*
 553 *cortex (dACC). The frontoparietal network (FPN) was defined using right and left anterior superior*
 554 *frontal gyrus (raSFG and laSFG), and right and left angular gyrus (rAG and lAG). The dorsal*
 555 *attention Network (DAN) was defined using right and left intraparietal sulcus (rIPS and lIPS).*

556


557

558




559

560 *Figure 3. Group differences between PSC and NC in grey matter volume (left panel) and*
 561 *functional connectivity between nodes within four large scale networks (right panel). Hot colour*
 562 *scheme indicates the strength of effect size of PSC showing higher GMV and FC than NC, while cold*
 563 *colour scheme indicates the opposite effect (i.e. NC > PSC).*



564

565 *Figure 4. PLS analysis of grey matter volume (GMV) and cognition indicating the spatial*
 566 *distribution of GMV loading values (a), where hot and cold colour schemes are used for the strength*
 567 *of positive and negative correlations with the profile of Cognitive LV (b). (c) The scatter plot on the*
 568 *left represents the relationship between subjects scores of GMV LV and Cognition LV for*
 569 *presymptomatic carriers (PSC) and non-carriers (NC). The scatter plots in the middle and right*
 570 *hand-side represent GMV-Cognition LV relationship as a function of expected years to onset (EYO,*
 571 *split in two groups, Near and Far, see text) in each gene group separately.*



572

573 *Figure 5. PLS analysis of functional connectivity and cognition indicating the connectivity*
 574 *pattern of loading values (a), where hot and cold colour schemes are used for the strength of*
 575 *positive and negative correlations with the profile of Cognitive LV (b). (c) The scatter plot on the*
 576 *left represents the relationship between subjects scores of Function LV and Cognition LV for*
 577 *presymptomatic carriers (PSC) and non-carriers (NC). The scatter plots in the middle and right*
 578 *hand-side represents Function-Cognition LV relationship as a function of expected years to onset*
 579 *(EYO split in two groups, Near and Far, see text) in each gene group separately, which is also*
 580 *represented using a bar chart in (d). * denotes significant test at p-value < 0.05.*

581 9. APPENDIX

- 582 List of other GENFI consortium members
- 583 Sónia Afonso - Instituto Ciências Nucleares Aplicadas a Saude, Universidade de Coimbra, Coimbra, Portugal
- 584 Maria Rosario Almeida - Centre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, Portugal
- 585 Sarah Anderl-Straub – Department of Neurology, Ulm University, Ulm, GermanyChristin Andersson - Department of
- 586 Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- 587 Anna Antonell - Alzheimer’s disease and other cognitive disorders unit, Neurology Department, Hospital Clinic,
- 588 Institut d’Investigacions Biomèdiques, Barcelona, Spain
- 589 Silvana Archetti - Biotechnology Laboratory, Department of Diagnostics, Spedali Civili Hospital, Brescia, Italy
- 590 Andrea Arighi - Fondazione IRCSS Ca’ Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit,
- 591 Milan, Italy
- 592 Mircea Balasa - Alzheimer’s disease and other cognitive disorders unit, Neurology Department, Hospital Clinic,
- 593 Institut d’Investigacions Biomèdiques, Barcelona, Spain
- 594 Myriam Barandiaran - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014,
- 595 San Sebastian, Gipuzkoa, Spain
- 596 Nuria Bargalló - Radiology Department, Image Diagnosis Center, Hospital Clínic and Magnetic Resonance Image core
- 597 facility, IDIBAPS, Barcelona, Spain
- 598 Robart Bartha - Department of Medical Biophysics, Robarts Research Institute, University of Western Ontario,
- 599 London, Ontario, Canada
- 600 Benjamin Bender - Department of Diagnostic and Interventional Neuroradiology, University of Tuebingen,
- 601 Tuebingen, Germany
- 602 Luisa Benussi - Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli,
- 603 Brescia, Italy
- 604 Valentina Bessi - Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence,
- 605 Florence, Italy
- 606 Giuliano Binetti - Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio
- 607 Fatebenefratelli, Brescia, Italy
- 608 Sandra Black - LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, Canada
- 609 Martina Bocchetta – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of
- 610 Neurology, Queen Square London, UK
- 611 Sergi Borrego-Ecija - Alzheimer’s disease and other cognitive disorders unit, Neurology Department, Hospital Clinic,
- 612 Institut d’Investigacions Biomèdiques, Barcelona, Spain
- 613 Jose Bras – Dementia Research Institute, Department of Neurodegenerative Disease, UCL Institute of Neurology,
- 614 Queen Square, London, UK
- 615 Rose Bruffaerts - Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
- 616 Paola Caroppo - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan,
- 617 Italy
- 618 David Cash – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
- 619 Queen Square, London, UK
- 620 Miguel Castelo-Branco - Neurology Department, Centro Hospitalar e Universitário de Coimbra, Instituto de Ciências
- 621 Nucleares Aplicadas à Saúde (ICNAS), Coimbra, Portugal
- 622 Rhian Convery – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
- 623 Queen Square, London, UK
- 624 Thomas Cope – Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK
- 625 Maura Cosseddu – Centre for Neurodegenerative Disorders, Neurology Unit, Spedali Civili Hospital, Brescia, Italy
- 626 María de Arriba - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San
- 627 Sebastian, Gipuzkoa, Spain
- 628 Giuseppe Di Fede - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta,
- 629 Milan, Italy
- 630 Zigor Díaz - CITA Alzheimer, San Sebastian, Spain

631 Katrina M Moore – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of
632 Neurology, Queen Square, London, UK
633 Diana Duro - Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal
634 Chiara Fenoglio - University of Milan, Centro Dino Ferrari, Milan, Italy
635 Camilla Ferrari - Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence,
636 Florence, Italy
637 Carlos Ferreira - Instituto Ciências Nucleares Aplicadas à Saúde, Universidade de Coimbra, Coimbra, Portugal
638 Catarina B. Ferreira - Faculty of Medicine, University of Lisbon, Lisbon, Portugal
639 Toby Flanagan – Faculty of Biology, Medicine and Health, Division of Neuroscience and Experimental Psychology,
640 University of Manchester, Manchester, UK
641 Nick Fox – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
642 Queen Square, London, UK
643 Morris Freedman - Division of Neurology, Baycrest Centre for Geriatric Care, University of Toronto, Toronto, Canada
644 Giorgio Fumagalli - Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit,
645 Milan, Italy; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence,
646 Florence, Italy
647 Alazne Gabilondo - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San
648 Sebastian, Gipuzkoa, Spain
649 Roberto Gasparotti - Neuroradiology Unit, University of Brescia, Brescia, Italy
650 Serge Gauthier - Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada
651 Stefano Gazzina - Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental
652 Sciences, University of Brescia, Brescia, Italy
653 Giorgio Giaccone - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta,
654 Milan, Italy
655 Ana Gorostidi - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San
656 Sebastian, Gipuzkoa, Spain
657 Caroline Greaves – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of
658 Neurology, Queen Square London, UK
659 Rita Guerreiro – Dementia Research Institute, Department of Neurodegenerative Disease, UCL Institute of
660 Neurology, London, UK
661 Carolin Heller – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
662 Queen Square, London, UK
663 Tobias Hoegen - Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany
664 Begoña Indakoetxea - Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, Paseo Dr
665 Begiristain sn, CP 20014, San Sebastian, Gipuzkoa, Spain
666 Vesna Jelic - Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden
667 Lize Jiskoot - Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
668 Hans-Otto Karnath - Section of Neuropsychology, Department of Cognitive Neurology, Center for Neurology &
669 Hertie-Institute for Clinical Brain Research, Tübingen, Germany
670 Ron Keren - University Health Network Memory Clinic, Toronto Western Hospital, Toronto, Canada
671 Maria João Leitão - Centre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, Portugal
672 Albert Lladó - Alzheimer's disease and other cognitive disorders unit, Neurology Department, Hospital Clinic, Institut
673 d'Investigacions Biomèdiques, Barcelona, Spain
674 Gemma Lombardi - Department of Neuroscience, Psychology, Drug Research and Child Health, University of
675 Florence, Florence, Italy
676 Sandra Loosli - Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany
677 Carolina Maruta - Lisbon Faculty of Medicine, Language Research Laboratory, Lisbon, Portugal
678 Simon Mead - MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen
679 Square, London, UK
680 Lieke Meeter - Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands
681 Gabriel Miltenberger - Faculty of Medicine, University of Lisbon, Lisbon, Portugal
682 Rick van Minkelen - Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
683 Sara Mitchell - LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, Canada

684 Benedetta Nacmias - Department of Neuroscience, Psychology, Drug Research and Child Health, University of
685 Florence, Florence, Italy
686 Mollie Neason - Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
687 Queen Square, London, UK
688 Jennifer Nicholas – Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
689 Linn Öijerstedt - Department of Geriatric Medicine, Karolinska Institutet, Stockholm, Sweden
690 Jaume Olives - Alzheimer’s disease and other cognitive disorders unit, Neurology Department, Hospital Clinic, Institut
691 d’Investigacions Biomèdiques, Barcelona, Spain
692 Alessandro Padovani - Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and
693 Experimental Sciences, University of Brescia, Brescia, Italy
694 Jessica Panman – Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
695 Janne Papma - Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
696 Irene Piaceri - Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence,
697 Florence
698 Michela Pievani - Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio
699 Fatebenefratelli, Brescia, Italy
700 Yolande Pijnenburg - VUMC, Amsterdam, The Netherlands
701 Cristina Polito - Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, Nuclear Medicine Unit,
702 University of Florence, Florence, Italy
703 Enrico Premi - Stroke Unit, Neurology Unit, Spedali Civili Hospital, Brescia, Italy
704 Sara Prioni - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan,
705 Italy
706 Catharina Prix - Department of Neurology, Ludwig-Maximilians-University Munich, Germany
707 Rosa Rademakers - Department of Neurosciences, Mayo Clinic, Jacksonville, Florida, USA
708 Veronica Redaelli - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta,
709 Milan, Italy
710 Tim Rittman – Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
711 Ekaterina Rogaeva - Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto,
712 Canada
713 Pedro Rosa-Neto - Translational Neuroimaging Laboratory, McGill University Montreal, Québec, Canada
714 Giacomina Rossi - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta,
715 Milan, Italy
716 Martin Rossor – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
717 Queen Square, London, UK
718 Beatriz Santiago - Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
719 Elio Scarpini - University of Milan, Centro Dino Ferrari, Milan, Italy; Fondazione IRCCS Ca’ Granda, Ospedale Maggiore
720 Policlinico, Neurodegenerative Diseases Unit, Milan, Italy
721 Sonja Schönecker - Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany
722 Elisa Semler – Department of Neurology, Ulm University, Ulm, Germany
723 Rachelle Shafei – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
724 Queen Square, London, UK
725 Christen Shoemsmith - Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario,
726 Canada
727 Miguel Tábuas-Pereira - Centre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, Portugal
728 Mikel Tainta - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San
729 Sebastian, Gipuzkoa, Spain
730 Ricardo Taipa - Neuropathology Unit and Department of Neurology, Centro Hospitalar do Porto - Hospital de Santo
731 António, Oporto, Portugal
732 David Tang-Wai - University Health Network Memory Clinic, Toronto Western Hospital, Toronto, Canada
733 David L Thomas - Neuroradiological Academic Unit, UCL Institute of Neurology, London, UK
734 Hakan Thonberg - Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Stockholm,
735 Sweden
736 Carolyn Timberlake - University of Cambridge, Cambridge, UK

737 Pietro Tiraboschi - Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta,
738 Milano, Italy
739 Philip Vandamme - Neurology Service, University Hospitals Leuven, Belgium; Laboratory for Neurobiology, VIB-KU
740 Leuven Centre for Brain Research, Leuven, Belgium
741 Mathieu Vandenbulcke - Geriatric Psychiatry Service, University Hospitals Leuven, Belgium; Neuropsychiatry,
742 Department of Neurosciences, KU Leuven, Leuven, Belgium
743 Michele Veldsman - University of Oxford, UK
744 Ana Verdelho - Department of Neurosciences, Santa Maria Hospital, University of Lisbon, Portugal
745 Jorge Villanua - OSATEK Unidad de Donostia, San Sebastian, Gipuzkoa, Spain
746 Jason Warren – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology,
747 Queen Square, London, UK
748 Carlo Wilke - Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany
749 Ione Woollacott – Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of
750 Neurology, Queen Square, London, UK
751 Elisabeth Wlasich - Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany
752 Henrik Zetterberg - Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
753 Miren Zulaica - Neuroscience Area, Biodonostia Health Research Institute, Paseo Dr Begiristain sn, CP 20014, San
754 Sebastian, Gipuzkoa, Spain.
755